New directions in the experimental therapy of tick-borne encephalitis
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu přehledy, časopisecké články, práce podpořená grantem
PubMed
36574904
DOI
10.1016/j.antiviral.2022.105504
PII: S0166-3542(22)00273-X
Knihovny.cz E-zdroje
- Klíčová slova
- Antivirals, Immunotherapy, Monoclonal antibodies, Tick-borne encephalitis, Tick-borne encephalitis virus,
- MeSH
- experimentální terapie MeSH
- klíšťová encefalitida * MeSH
- lidé MeSH
- myši MeSH
- viry klíšťové encefalitidy * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Geografické názvy
- Asie MeSH
- Evropa MeSH
Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. There is no specific therapy for the treatment of TBE patients. However, several efforts are being made to develop small molecules that specifically interfere with the life cycle of TBE virus. In particular, recently various nucleoside analogues that can inhibit the viral replicase, such as the RNA-dependent RNA polymerase or viral methyltransferases, have been explored. In addition, human or chimeric (i.e., structural chimeras that combine mouse variable domains with human constant domains) monoclonal antibodies with promising potential for post-exposure prophylaxis or early therapy have been developed. This review summarizes the latest directions and experimental approaches that may be used to combat TBE in humans.
Citace poskytuje Crossref.org
